Table 3 Median survival estimates (months) by treatment and frailty group.

From: Ixazomib with cyclophosphamide and dexamethasone in relapsed or refractory myeloma: MUKeight phase II randomised controlled trial results

  

ICD Median (80% CI)

CD Median (80% CI)

PFS

Non-frail

5.1 (3.5–5.6)

7.0 (4.7–16.0)

Frail

6.7 (4.1–8.0)

5.6 (3.7–6.9)

OS

Non-frail

15.3 (12.5–3.08)

Not estimated

Frail

14.1 (11.1–15.7)

18.0 (13.0-not estimated)

Back to article page